CRSP CRISPR Therapeutics
- 50.590
- -0.170-0.33%
- 50.030
- -0.560-1.11%
CRISPR Therapeutics News
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
CRISPR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
CRISPR Therapeutics | 10-Q: Q2 2024 Earnings Report
CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director George Simeon
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Treco Douglas A
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director High Katherine A
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Greene John
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Mahatme Sandesh
CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Rommel Christian
Analysis
Price Target
No Data
No Data
